Gilead Stock Calculator
Estimate your Gilead ($GILD) stock returns over time
Gilead Investment Calculator
Calculate potential returns on your Gilead stock investment using historical performance data.
Investment Projection Results
Initial Investment:
—
Hold Period:
—
Expected Annual Return:
—
Future Value:
—
Total Return:
—
What This Means For You
Enter your investment details above to see personalized insights.
Investment Growth Over Time
Frequently Asked Questions
This calculator allows you to project returns on Gilead stock over time. Input your initial investment, holding period, and return rate. Experiment with different values to see how compounding impacts your potential growth.
Gilead has demonstrated varying returns across different time periods. The 5Y return of 72.55% provides the most comprehensive historical view. Our weighted average annual return of 77.48% gives more weight to longer-term performance. However, past performance doesn't guarantee future results, and returns can vary significantly year to year.
Several factors can influence Gilead's stock performance:
- Company earnings and revenue growth
- Market conditions and economic trends
- Industry-specific developments
- Company announcements and news
- Overall market sentiment
The calculator provides two key metrics:
Future Value
The projected value of your investment at the end of your holding period
Total Return
The absolute dollar amount gained or lost, plus the percentage return on your investment
Remember that these are projections based on your inputs and historical data. Actual returns may differ significantly.
Explore More Stock Calculators
Historical Returns
1Y Return
76.50%
2Y Return
53.24%
3Y Return
89.64%
4Y Return
94.09%
5Y Return
72.55%
YTD Return
19.83%
Last Updated: 2025-06-04 14:21:19
Gilead Information
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Business Classification
Sector
Healthcare
Industry
Drug Manufacturers - General
Location
Foster City, CA, United States
Company Size
17,600 employees
Website
Resources & Data Sources
Stock data powered by
Yahoo Finance API
Company logos provided by
Parqet Logo API
Market data and calculations are for informational purposes only and should not be considered as financial advice.
